Article
Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.
Signal transduction and targeted therapy - 23 Dec 2025
Shen Ke-Yu, Yu Shi-Zhe, Su Ying-Han, Xie Sun-Zhe, Zhang Chen, Xu Hao, Yang SamI, Zou Tian-Tian, Fu Yan, Wang Hao, Fang Lin, Zheng Yan, Su Chang-Qing, Qin Lun-Xiu
Abstract excerpt
Neoantigen vaccines and oncolytic viruses are emerging immunotherapies that can reshape the tumor microenvironment (TME). However, tumors with low mutation burdens often respond poorly to immunotherapies because of their limited immunogenicity. Developing effective immunotherapy strategies for these types of tumors remains a significant challenge. In this study, we engineered oncolytic adenoviruses to accurately...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.